[1]Valent, P.; Schernthaner, G. H.; Sperr, W. R.; Fritsch, G.; Agis, H.; Willheim, M.; Buhring, H. J.; Orfao, A. und Escribano, L. (2001): Variable expression of activation-linked surface antigens on human mast cells in health and disease, Immunol Rev 179, Seite 74-81.[1]Valent, P.; Schernthaner, G. H.; Sperr, W. R.; Fritsch, G.; Agis, H.; Willheim, M.; Buhring, H. J.; Orfao, A. und Escribano, L. (2001): Variable expression of activation-linked surface antigens on human mast cells in health and disease, Immunol Rev 179, Seite 74-81.

[2](2002): Mini Symposium 3: Mast cell and basophils, Allergy 57 [Suppl 73], Seite 11-12.

[3]Henz, B. M.; Maurer, M.; Lippert, U.; Worm, M. und Babina, M. (2001): Mast cells as initiators of immunity and host defense, Exp Dermatol 10 [1], Seite 1-10.

[4]Ehrlich, Paul (1878): Beiträge zur Therapie und Praxis der histologischen Färbung, Dissertation der Universität Leipzig.

[5]Kirshenbaum, A. S.; Kessler, S. W.; Goff, J. P. und Metcalfe, D. D. (1991): Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells, Journal of Immunology 146 [5], Seite 1410-1415.

[6]Janeway, C.A. Travers, P (1997): Immunologie, 2. Auflage. Auflage, Spektrum

Akademischer Verlag.

[7]Bradding, P. und Holgate, S. T. (1999): Immunopathology and human mast cell cytokines, Crit Rev Oncol Hematol 31 [2], Seite 119-33.

[8]Gurish, M. F. und Austen, K. F. (2001): The diverse roles of mast cells, J Exp Med 194 [1], Seite F1-5.

[9]Lorentz, A.; Schuppan, D.; Gebert, A.; Manns, M. P. und Bischoff, S. C. (2002): Regulatory effects of stem cell factor and interleukin-4 on human mast cells to extracellular matrix proteins, Blood 99 [3], Seite 966-972.

[10]Pawankar, R. ; Okuda, M.; Yssel, H. ; Okumura, K. und Ra, Ch. (1997): Nasal Mast Cells in Perennial Allergic Rhinitics Exhibit Increased Expression of the FceRI, CD40L, IL-4 and IL-13, and can Induce IgE Synthesis in B Cells, J. Clin. Invest. 99 [7], Seite 1492-1499.

[11]Shelburne, C. P. und Ryan, J. J. (2001): The role of Th2 cytokines in mast cell homeostasis, Immunol Rev 179, Seite 82-93.

[12]Algermissen, B.; Hermes, B.; Feldmann-Boeddeker, I.; Bauer, F. und Henz, B. M. (1999): Mast cell chymase and tryptase during tissue turnover: analysis on in vitro mitogenesis of fibroblasts and keratinocytes and alterations in cutaneous scars, Exp Dermatol 8 [3], Seite 193-8.

[13]Matsunaga, Y. und Terada, T. (2000): Mast cell subpopulations in chronic inflammatory hepatobiliary diseases, Liver 20 [2], Seite 152-6.

[14]Beil, W. J. und Pammer, J. (2001): In situ detection of the mast cell proteases chymase and tryptase in human lung tissue using light and electron microscopy, Histochem Cell Biol 116 [6], Seite 483-93.

[15]Buckley, M. G.; McEuen, A. R. und Walls, A. F. (1999): The detection of mast cell subpopulations in formalin-fixed human tissues using a new monoclonal antibody specific for chymase, J Pathol 189 [1], Seite 138-43.

[16]Bradding, P.; Okayama, Y.; Howarth, P. H.; Church, M. K. und Holgate, S. T. (1995): Heterogeneity of human mast cells based on cytokine content, J Immunol 155 [1], Seite 297-307.

[17]Ghannadan, M.; Baghestanian, M.; Wimazal, F.; Eisenmenger, M.; Latal, D.; Kargul, G.; Walchshofer, S.; Sillaber, C.; Lechner, K. und Valent, P. (1998): Phenotypic characterization of human skin mast cells by combined staining with toluidine blue and CD antibodies, J Invest Dermatol 111 [4], Seite 689-95.

[18]Saarinen, J. V.; Harvima, R. J.; Naukkarinen, A.; Horsmanheimo, M. und Harvima, I. T. (2001): Interleukin-4-positive mast cells are highly associated with the extent of immediate allergic wheal reaction in the skin, Allergy 56 [1], Seite 58-64.

[19]Bauer, O. und Razin, E. (2000): Mast Cell-Nerve Interactions, News Physiol Sci 15, Seite 213-218.

[20]Pawankar, R. (2001): Mast cells as orchestrators of the allergic reaction: the IgE-IgE receptor mast cell network, Curr Opin Allergy Clin Immunol 1 [1], Seite 3-6.

[21]Saarinen, J. V.; Harvima, R. J.; Naukkarinen, A.; Horsmanheimo, M. und Harvima, I. T. (2001): The release of histamine is associated with the inactivation of mast cell chymase during immediate allergic wheal reaction in the skin, Clin Exp Allergy 31 [4], Seite 593-601.

[22]Worm, M. und Henz, B. M. (1997): Molecular mechanisms of IgE regulation, Hautarzt 48 [10], Seite 773-82.

[23]Church, M. K.; Okayama, Y. und Bradding, P. (1994): The role of the mast cell in acute and chronic allergic inflammation, Ann N Y Acad Sci 725, Seite 13-21.

[24]Bradding, P. und Conley, E. C. (2002): Human mast cell ion channels, Clin Exp Allergy 32 [7], Seite 979-83.

[25]Kraneveld, A. D.; Van Der Kleij, H. P.; Kool, M.; Van Houwelingen, A. H.; Weitenberg, A. C.; Redegeld, F. A. und Nijkamp, F. P. (2002): Key role for mast cells in nonatopic asthma, J Immunol 169 [4], Seite 2044-53.

[26]Bradding, P. ; Feather, I. H. ; Wilson, S. ; Bardin, P. G. ; Heusser, C. H.; Holgate, S. T. und Howarth, P. H. (1993): Immunolocalization of Cytokines in the Nasal Mucosa of Normal and Perennial Rhinitic Subjects, Journal of Immunology 151 [7], Seite 3853-3865.

[27]Di Lorezo, G.; Drago, A. ; Pellitteri, M. E.; Candore, G.; Colombo, A. und Caruso, C. (2001): Measurement of Inflammatory Mediators of Mast Cells and Eosinophils in Native Nasal Lavage Fluid in Nasal Polyposis, Int Arch Allergy Immunol [125], Seite 164-175.

[28]Nielsen, L. P.; Mygind, N. und Dahl, R. (2001): Intranasal corticosteroids for allergic rhinitis: superior relief?, Drugs 61 [11], Seite 1563-79.

[29]Demitsu, T.; Inoue, T.; Kakurai, M.; Kiyosawa, T.; Yoneda, K. und Manabe, M. (2002): Activation of mast cells within a tumor of angiosarcoma: ultrastructural study of five cases, J Dermatol 29 [5], Seite 280-9.

[30]Sugerman, P. B.; Savage, N. W.; Walsh, L. J.; Zhao, Z. Z.; Zhou, X. J.; Khan, A.; Seymour, G. J. und Bigby, M. (2002): The pathogenesis of oral lichen planus, Crit Rev Oral Biol Med 13 [4], Seite 350-65.

[31]Zhao, Z. Z. ; Savage, N. W. und Walsh, L. J. (1998): Associations between mast cells and laminin in oral lichen planus, J Oral Pathol Med 27 [4], Seite 163-7.

[32]Zhao, Z. Z.; Savage, N. W.; Sugerman, P. B. und Walsh, L. J. (2002): Mast cell/T cell interactions in oral lichen planus, J Oral Pathol Med 31 [4], Seite 189-95.

[33]Riede, UN (1998): Taschenatlas der allgemeinen Pathologie, Thieme.

[34]Church, M. K.; Lowman, M. A.; Rees, P. H. und Benyon, R. C. (1989): Mast cells, neuropeptides and inflammation, Agents Actions 27 [1-2], Seite 8-16.

[35]Artuc, M.; Hermes, B.; Steckelings, U. M.; Grutzkau, A. und Henz, B. M. (1999): Mast cells and their mediators in cutaneous wound healing--active participants or innocent bystanders?, Exp Dermatol 8 [1], Seite 1-16.

[36]Stassen, M.; Hultner, L.; Muller, C. und Schmitt, E. (2002): Mast cells and inflammation, Arch Immunol Ther Exp (Warsz) 50 [3], Seite 179-85.

[37]Hermes, B.; Welker, P.; Feldmann-Boddeker, I.; Kruger-Krasagakis, S.; Hartmann, K.; Zuberbier, T. und Henz, B. M. (2001): Expression of mast cell growth modulating and chemotactic factors and their receptors in human cutaneous scars, J Invest Dermatol 116 [3], Seite 387-93.

[38]Blair, R. J. ; Homg, M. ; Marchese, M.J.; Ren, Sh. und Gruber, B. L. (1997): Human Mast Cells Stimulate Vascular Tube Formation, J. Clin. Invest. 99 [11], Seite 2691-2700.

[39]Gruber, B. L.; Marchese, M. J. und Kew, R. (1995): Angiogenic factors stimulate mast-cell migration, Blood 86 [7], Seite 2488-93.

[40]Levi-Schaffer, F. und Pe'er, J. (2001): Mast cells and angiogenesis, Clin Exp Allergy 31 [4], Seite 521-4.

[41]Huttunen, M.; Aalto, M. L.; Harvima, R. J.; Horsmanheimo, M. und Harvima, I. T. (2000): Alterations in mast cells showing tryptase and chymase activity in epithelializating and chronic wounds, Exp Dermatol 9 [4], Seite 258-65.

[42]Czarnetzki, B. M.; Grabbe, J.; Kolde, G.; Kruger-Krasagakes, S.; Welker, P. und Zuberbier, T. (1995): Mast cells in the cytokine network: the what, where from and what for, Exp Dermatol 4 [4 Pt 2], Seite 221-6.

[43]Hermes, B. ; Feldmann-Böddeker, I. ; Welker, P. ; Algermissen, B.; Steckelings, M. U.; Grabbe, J. und Henz, B. M. (2000): Altered Expression of Mast Cell Chymase and Tryptase and of c-Kit in Human Cutaneous Scar Tissue, J Invest Dermatol 114, Seite 51-55.

[44]Trautmann, A.; Krohne, G.; Brocker, E. B. und Klein, C. E. (1998): Human mast cells augment fibroblast proliferation by heterotypic cell-cell adhesion and action of IL-4, J Immunol 160 [10], Seite 5053-7.

[45]Gibbs, B. F.; Wierecky, J.; Welker, P.; Henz, B. M.; Wolff, H. H. und Grabbe, J. (2001): Human skin mast cells rapidly release preformed and newly generated TNF-alpha and IL-8 following stimulation with anti-IgE and other secretagogues, Exp Dermatol 10 [5], Seite 312-20.

[46]Holgate, S. T.; Benyon, R. C.; Lowman, M. A. und Church, M. K. (1989): Activation of human mast cells after immunoglobulin E-dependent and neuropeptide stimulation, Prog Clin Biol Res 297, Seite 103-12; discussion 112-3.

[47]Lowman, M. A.; Benyon, R. C. und Church, M. K. (1988): Characterization of neuropeptide-induced histamine release from human dispersed skin mast cells, Br J Pharmacol 95 [1], Seite 121-30.

[48]Lowman, M. A.; Rees, P. H.; Benyon, R. C. und Church, M. K. (1988): Human mast cell heterogeneity: histamine release from mast cells dispersed from skin, lung, adenoids, tonsils, and colon in response to IgE-dependent and nonimmunologic stimuli, J Allergy Clin Immunol 81 [3], Seite 590-7.

[49]Berger, P.; N'Guyen, C.; Buckley, M.; Scotto-Gomez, E.; Marthan, R. und Tunon-De-Lara, J. M. (2002): Passive sensitization of human airways induces mast cell degranulation and release of tryptase, Allergy 57 [7], Seite 592-9.

[50]Mayr, S. I.; Zuberi, R. I.; Zhang, M.; de Sousa-Hitzler, J.; Ngo, K.; Kuwabara, Y.; Yu, L.; Fung-Leung, W. P. und Liu, F. T. (2002): IgE-dependent mast cell activation potentiates airway responses in murine asthma models, J Immunol 169 [4], Seite 2061-8.

[51]Ferry, X.; Brehin, S.; Kamel, R. und Landry, Y. (2002): G protein-dependent activation of mast cell by peptides and basic secretagogues, Peptides 23 [8], Seite 1507.

[52]Tkaczyk, C.; Metcalfe, D. D. und M., Gilfillan A. (2002): FcyRI and Other Fc Receptors on Human Mast Cells, ACI International 14 [3], Seite 109-115.

[53]Baumruker, T. und Prieschl, E.E. (2001): Mast Cells and their Activation - from the Molecular Mechanisms to Clinical Relevance, Mod. Asp. Immunobiol. 1 [6], Seite 259-262.

[54]Ohtake, H.; Ichikawa, N.; Okada, M. und Yamashita, T. (2002): Transmembrane Phosphoprotein Csk-Binding Protein/ Phosphoprotein Associated With Glycosphingolipid-Enriched Microdomains as a Negative Feedback Regulator of Mast Cell Signaling Through the FceRI, Journal of Immunology 168, Seite 2087-2090.

[55]Ornitz, D. M. und Itoh, N. (2001): Fibroblast growth factors, Genome Biol 2 [3], Seite REVIEWS3005.

[56]Klagsbrun, M. (1989): The fibroblast growth factor family: structural and biological properties, Prog Growth Factor Res 1 [4], Seite 207-35.

[57]Nugent, M. A. und Iozzo, R. V. (2000): Fibroblast growth factor-2, Int J Biochem Cell Biol 32 [2], Seite 115-20.

[58]Hamada, H.; Vallyathan, V.; Cool, C. D.; Barker, E.; Inoue, Y. und Newman, L. S. (2000): Mast cell basic fibroblast growth factor in silicosis, Am J Respir Crit Care Med 161 [6], Seite 2026-34.

[59]Qu, Z.; Huang, X.; Ahmadi, P.; Stenberg, P.; Liebler, J. M.; Le, A. C.; Planck, S. R. und Rosenbaum, J. T. (1998): Synthesis of basic fibroblast growth factor by murine mast cells. Regulation by transforming growth factor beta, tumor necrosis factor alpha, and stem cell factor, Int Arch Allergy Immunol 115 [1], Seite 47-54.

[60]Reed, J. A.; Albino, A. P. und McNutt, N. S. (1995): Human cutaneous mast cells express basic fibroblast growth factor, Lab Invest 72 [2], Seite 215-22.

[61]Artuc, M.; Steckelings, U. M. und Henz, B. M. (2002): Mast cell-fibroblast interactions: human mast cells as source and inducers of fibroblast and epithelial growth factors, J Invest Dermatol 118 [3], Seite 391-5.

[62]Okada - Ban, M.; Thiery, J. P. und Jouanneau, J. (2000): Fibroblast growth factor - 2, The International Journal of Biochemistry & and Cell Biology 32, Seite 263-267.

[63]Loo, B. M.; Kreuger, J.; Jalkanen, M.; Lindahl, U. und Salmivirta, M. (2001): Binding of heparin/heparan sulfate to fibroblast growth factor receptor 4, J Biol Chem 276 [20], Seite 16868-76.

[64]Brown, K. J.; Hendry, I. A. und Parish, C. R. (1995): Acidic and basic fibroblast growth factor bind with differing affinity to the same heparan sulfate proteoglycan on BALB/c 3T3 cells: implications for potentiation of growth factor action by heparin, J Cell Biochem 58 [1], Seite 6-14.

[65]Chang, Z.; Meyer, K.; Rapraeger, A. C. und Friedl, A. (2000): Differential ability of heparan sulfate proteoglycans to assemble the fibroblast growth factor receptor complex in situ, Faseb J 14 [1], Seite 137-44.

[66]Moscatelli, D. (1992): Basic fibroblast growth factor (bFGF) dissociates rapidly from heparan sulfates but slowly from receptors. Implications for mechanisms of bFGF release from pericellular matrix, J Biol Chem 267 [36], Seite 25803-9.

[67]Wong, P.; Hampton, B.; Szylobryt, E.; Gallagher, A. M.; Jaye, M. und Burgess, W. H. (1995): Analysis of putative heparin-binding domains of fibroblast growth factor-1. Using site-directed mutagenesis and peptide analogues, J Biol Chem 270 [43], Seite 25805-11.

[68]Wong, P. und Burgess, W. H. (1998): FGF2-Heparin co-crystal complex-assisted design of mutants FGF1 and FGF7 with predictable heparin affinities, J Biol Chem 273 [29], Seite 18617-22.

[69]Pellegrini, L.; Burke, D. F.; von Delft, F.; Mulloy, B. und Blundell, T. L. (2000): Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin, Nature 407 [6807], Seite 1029-34.

[70]Dowd, C. J.; Cooney, C. L. und Nugent, M. A. (1999): Heparan sulfate mediates bFGF transport through basement membrane by diffusion with rapid reversible binding, J Biol Chem 274 [8], Seite 5236-44.

[71]Nagendra, H. G.; Harrington, A. E.; Harmer, N. J.; Pellegrini, L.; Blundell, T. L. und Burke, D. F. (2001): Sequence analyses and comparative modeling of fly and worm fibroblast growth factor receptors indicate that the determinants for FGF and heparin binding are retained in evolution, FEBS Lett 501 [1], Seite 51-8.

[72]Pellegrini, L. (2001): Role of heparan sulfate in fibroblast growth factor signalling: a structural view, Curr Opin Struct Biol 11 [5], Seite 629-34.

[73]D'Amore, P. A. (1990): Modes of FGF release in vivo and in vitro, Cancer Metastasis Rev 9 [3], Seite 227-38.

[74]Qu, Z.; Liebler, J. M.; Powers, M. R.; Galey, T.; Ahmadi, P.; Huang, X. N.; Ansel, J. C.; Butterfield, J. H.; Planck, S. R. und Rosenbaum, J. T. (1995): Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma, Am J Pathol 147 [3], Seite 564-73.

[75]Qu, Z.; Kayton, R. J.; Ahmadi, P.; Liebler, J. M.; Powers, M. R.; Planck, S. R. und Rosenbaum, J. T. (1998): Ultrastructural immunolocalization of basic fibroblast growth factor in mast cell secretory granules. Morphological evidence for bfgf release through degranulation, J Histochem Cytochem 46 [10], Seite 1119-28.

[76]Neufeld, G. und Gospodarowicz, D. (1986): Basic and acidic fibroblast growth factors interact with the same cell surface receptors, J Biol Chem 261 [12], Seite 5631-7.

[77]Ballinger, M. D.; Shyamala, V.; Forrest, L. D.; Deuter-Reinhard, M.; Doyle, L. V.; Wang, J. X.; Panganiban-Lustan, L.; Stratton, J. R.; Apell, G.; Winter, J. A.; Doyle, M. V.; Rosenberg, S. und Kavanaugh, W. M. (1999): Semirational design of a potent, artificial agonist of fibroblast growth factor receptors, Nat Biotechnol 17 [12], Seite 1199-204.

[78]Knox, S.; Merry, C.; Stringer, S.; Melrose, J. und Whitelock, J. (2002): Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors, J Biol Chem 277 [17], Seite 14657-65.

[79]Strutz, F.; Zeisberg, M.; Renziehausen, A.; Raschke, B.; Becker, V.; van Kooten, C. und Muller, G. (2001): TGF-beta 1 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth factor (FGF-2), Kidney Int 59 [2], Seite 579-92.

[80]Facchiano, F.; Lentini, A.; Fogliano, V.; Mancarella, S.; Rossi, C.; Facchiano, A. und Capogrossi, M. C. (2002): Sugar-induced modification of fibroblast growth factor 2 reduces its angiogenic activity in vivo, Am J Pathol 161 [2], Seite 531-41.

[81]Powers, M. R.; Qu, Z.; LaGesse, P. C.; Liebler, J. M.; Wall, M. A. und Rosenbaum, J. T. (1998): Expression of basic fibroblast growth factor in nasal polyps, Ann Otol Rhinol Laryngol 107 [10 Pt 1], Seite 891-7.

[82]Qu, Z.; Huang, X. N.; Ahmadi, P.; Andresevic, J.; Planck, S. R.; Hart, C. E. und Rosenbaum, J. T. (1995): Expression of basic fibroblast growth factor in synovial tissue from patients with rheumatoid arthritis and degenerative joint disease, Lab Invest 73 [3], Seite 339-46.

[83]Akimoto, S.; Ishikawa, O.; Iijima, C. und Miyachi, Y. (1999): Expression of basic fibroblast growth factor and its receptor by fibroblast, macrophages and mast cells in hypertrophic scar, Eur J Dermatol 9 [5], Seite 357-62.

[84]Yamamoto, T.; Katayama, I. und Nishioka, K. (1995): Involvement of basic fibroblast growth factor in fibroblast-stimulatory serum activity of a patient with systemic lupus erythematosus and multiple dermatofibromas, Dermatology 191 [4], Seite 281-5.

[85]Murata, M.; Hara, K. und Saku, T. (1997): Dynamic distribution of basic fibroblast growth factor during epulis formation: an immunohistochemical study in an enhanced healing process of the gingiva, J Oral Pathol Med 26 [5], Seite 224-32.

[86]Norrby, K. (1994): Basic fibroblast growth factor and de novo mammalian angiogenesis, Microvasc Res 48 [1], Seite 96-113.

[87]Burchill, S. A. und Westwood, G. (2002): Mechanism of basic fibroblast growth factor-induced cell death, Apoptosis 7 [1], Seite 5-12.

[88]Strutz, F.; Zeisberg, M.; Ziyadeh, F. N.; Yang, C. Q.; Kalluri, R.; Muller, G. A. und Neilson, E. G. (2002): Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation, Kidney Int 61 [5], Seite 1714-28.

[89]Westwood, G.; Dibling, B. C.; Cuthbert-Heavens, D. und Burchill, S. A. (2002): Basic fibroblast growth factor (bFGF)-induced cell death is mediated through a caspase-dependent and p53-independent cell death receptor pathway, Oncogene 21 [5], Seite 809-24.

[90]Barillari, G. ; Sgadari, C. ; Palladino, C. ; Gendelman, R. ; Caputo, A. ; Morris, C.B. ; Nair, B.C. ; Markham, P. ; Nel, A. ; Sturzl, M. und Ensoli, B. (1999): Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin., J Immunol. 163 [4], Seite 1929-35.

[91]Leeman, S. E. und Ferguson, S. L. (2000): Substance P: an historical perspective, Neuropeptides 34 [5], Seite 249-54.

[92]Fiebich, B. L. und Lieb, K. (2001): Substanz P und neurogene Entzündung, Immunologie Aktuell 1 [6], Seite 148-149.

[93]Church, M. K.; Lowman, M. A.; Robinson, C.; Holgate, S. T. und Benyon, R. C. (1989): Interaction of neuropeptides with human mast cells, Int Arch Allergy Appl Immunol 88 [1-2], Seite 70-8.

[94]Andoh, T.; Nagasawa, T.; Satoh, M. und Kuraishi, Y. (1998): Substance P induction of itch-associated response mediated by cutaneous NK1 tachykinin receptors in mice, J Pharmacol Exp Ther 286 [3], Seite 1140-5.

[95]Church, M. K.; Benyon, R. C.; Lowman, M. A.; Hutson, P. A. und Holgate, S. T. (1989): Allergy or inflammation? From neuropeptide stimulation of human skin mast cells to studies on the mechanism of the late asthmatic response, Agents Actions 26 [1-2], Seite 22-30.

[96]Bradding, P. (1996): Human mast cell cytokines, Clin Exp Allergy 26 [1], Seite 13-9.

[97]Strutz, F.; Zeisberg, M.; Hemmerlein, B.; Sattler, B.; Hummel, K.; Becker, V. und Muller, G. A. (2000): Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation, Kidney Int 57 [4], Seite 1521-38.

[98]Vinkk, AA.; Shreedhar, V.; Roza, L.; Krutmann, J. und Kripke, ML. (1998): Cellular target of UVB-induced DNA damage resulting in lokal supression of contact hypersensitivity, J Photochem Photobiol B 44 [2], Seite 107-11.

[99]Ibbotson, SH; Lampert, CR; Moran, MN; Lynch, MC und Kochevar, IE (1998): Benzoyl peroxide increases UVA-induced plasma membrane damage and lipid oxidation in murine leukemia L1210 cells., J Invest Dermatol 110 [1], Seite 79-83.

[100]Mariano, TM; Vetrano, AM; Gentile, SL; Heck, DE; Whittemore, MS; Guillon, CD; Jabin, I; Rapp, RD; Heindel, ND und Laskin, JD (2002): Cell-impermeant pyridinium derivatives of psoralens as inhibitors of keratinocyte growth., Biochem Pharmacol 63 [1], Seite 31-9.

[101]Dvorak, A. M.; Morgan, E. S. und Weller, P. F. (2001): Ultrastructural immunolocalization of basic fibroblast growth factor to lipid bodies and secretory granules in human mast cells, Histochem J 33 [7], Seite 397-402.

[102]Hayashi, H; Tsuda, T; Tsurumi, N; Takai, Y; Maeda, M; Takahashi, K und Kimura, I (1987): Anticoagulant substance released from human lung mast cells by stimulation with anti-IgE or Ca-ionophore A23187, Acta Med Okayama 41 [2], Seite 85-7.

[103]Kuchtey, J und Fewtrell, C (1999): Protein kinase C activator PMA reduces the Ca(2+) response to antigen stimulation of adherent RBL-2H3 mucosal mast cells by inhibiting depletion of intracellular Ca(2+) stores., J Cell Physiol 181 [1], Seite 113-23.

[104]Okayama, Y; Uno, D; Hanawa, K und Kurosawa, M (1989): Effect of phorbol myristate acetate (PMA) on diphosphoinositide (DPI) synthesis in rat mast cells granules., Arerugi 38 [2], Seite 80-5.

[105]Yamaguchi, M; Sayama, K und Yano, K (1999): IgE enhances Fce receptor I expression and IgE-dependent release of histamine and lipid mediators from human umbilical cord blood-derived mast cells: synergistic effect of IL-4 and IgE on human mast cell Fce receptor I expression and mediator release . J Immunol 162, Seite 5455-5465.

[106]Bischoff, SC; Selige, G; Lorentz, A; Sebald, W; Raab, R und Manns, MP (1999): IL-4 enhances proliferation and mediator release in mature human mast cells., Proc Natl Acad Sci USA 96, Seite 8080-8085.

[107]LaVallee, TM; Tarantini, F; Gamble, S; Burgess, WH und Maciag, T (1996): Synaptotagmin-1 and FGF-1 homodimer are present as a high molecular weight complex in neutral tissue, FASEB J 10 [A1377].

[108]LaVallee, TM; Tarantini, F; Gamble, S; Mouta Carreira, C; Jackson, A und Maciag, T (1998): Synaptotagmin-1 is required for fibroblast growth factor-1 release., J Biol Chem 273 [35], Seite 22217-23.

[109]B. Alberts, D. Bray, A. Johnson (1999): Lehrbuch der Molekularen Zellbiologie, Wiley-VCH Verlag, ISBN: 3-527-30493-2.

[110]Skoog, ML; Ollinger, K und Skogh, M (1997): Microfluorometry using fluorescein diacetate reflects the integrity of the plasma membrane in UVA-irradiated cultured skin fibroblasts., Photodermatol Photoimmunol Photomed 13 [1-2], Seite 37-42.

[111]Gniadecki, R; Christoffersen, N und Wulf, HC (2002): Cholesterol-rich plasma membrane domains (lipid rafts) in keratinocytes: importance in the baseline and UVA-induced generation of reactive oxygen species., J Invest Dermatol 118 [4], Seite 582-8.